Swiss pharma company Roche’s insulin pump will be the next to support automated insulin delivery thanks to a partnership with French AI company Diabeloop.
As part of the deal, users will be able to integrate Roche’s Accu-Chek Insights insulin pump with the Diabeloop monitoring system. This integration would result in a hybrid closed-loop system – a system designed to take the pressure off the...
Medtronic’s MiniMed 770G System has landed FDA clearance for its hybrid closed-loop system, marking the first time an automated insulin delivery system was greenlighted for young children with Type 1 diabetes.
This clearance means that the tool can be marketed to children as young as 2. It can also be used for adults. The system includes an algorithm which is able to measure a patient’s glucose...
The American Diabetes Association's 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers and service providers highlighted new data as part of the virtual clinical conference. Read on for summaries of the studies and findings, as well as links to the online abstracts.
Onduo
Verily-backed diabetes management service Onduo, which combines a mobile app...
The FDA announced Friday a De Novo clearance for an interoperable automated glycemic controller device for use in a hybrid closed-loop diabetes management system.
Tandem Diabetes Care’s Control-IQ Technology acts as a new feature for the company’s t:slim X2 insulin pump (which was also cleared by the FDA back in February). The controller algorithm allows the pump and its connected system to...
Grenoble, France-based startup Diabeloop has secured €31m in a Series B funding round led by Cemag Invest, with ADAG, Odyssée Venture, previous backers Supernova Invest, Air Liquide Venture Capital and others also participating.
WHAT THEY DO
Founded in 2015 out of a medical research project, the company’s primary product is what is referred to as a hybrid closed-loop system for management of Type...
Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.
Collected from nearly 8 million days of recorded system use and announced by Medtronic today in a press release, the new findings also suggest that this rate increased further for those who employed...
